This inhibition reduced the expression of VCAM-1 and phosphorylated NF-κB (p-NFκB), thereby preventing BBB disruption in both relapsing-remitting MS (RRMS) and secondary progressive MS (SPMS). Here, NFKB1 is linked to secondary progressive multiple sclerosis.